Suven Life Sciences to Present Five Scientific Posters at AAIC 2026, Highlighting Phase-3 Masupirdine and Phase-2 Usmarapride Programs

What Happened ?

Key details

Conference Participation:

• Global Phase-3 Masupirdine clinical trial update for agitation associated with Alzheimer’s dementia.
• Usmarapride (SUVN-D4010) Phase-2 development update targeting cognitive disorders.
• SUVN-L16107, an M1 Positive Allosteric Modulator (PAM), healthy volunteer safety and pharmacokinetic study.
• SUVN-L1101142, a Muscarinic-4 Positive Allosteric Modulator for Alzheimer’s disease and schizophrenia.
• SUVN-N9503012, a selective 5-HT1A partial agonist for neurodegenerative disorders.

Strategic Objective:

• Present ongoing clinical and non-clinical research findings.
• Showcase progress across Suven’s neuroscience pipeline.
• Engage with global investigators and key opinion leaders.
• Explore strategic licensing, collaboration and partnering opportunities.
• Increase scientific visibility of its CNS development programs.

Company Pipeline Highlights:

Current advanced-stage programs include:

• Masupirdine (SUVN-502): Global Phase-3 trial ongoing for agitation associated with Alzheimer’s dementia.
• Usmarapride (SUVN-D4010): Phase-2 study in planning for cognitive disorders.
• SUVN-L16107: Phase-1 completed.
• Samelisant (SUVN-G3031): Phase-2 completed; Phase-3 planning underway.
• Ropanicant (SUVN-911): Phase-2a completed.
• Seven additional research-stage CNS programs are under development.

Note:

• The announcement relates to scientific dissemination of ongoing clinical research. It does not disclose new trial results, regulatory approvals, licensing agreements, or commercialization milestones.

Risk Analysis

Summary:

• The announcement is operationally positive from a research visibility perspective but carries limited immediate financial significance since no clinical outcomes or commercial transactions have been announced.

Key Risks:

• Conference presentations may not immediately translate into licensing or partnership agreements.
• Clinical development remains subject to regulatory approvals and future trial outcomes.
• Late-stage CNS drug development carries significant scientific and execution risks.
• Future commercialization depends on successful completion of clinical studies.

Worst Case:

• If future clinical data fail to meet efficacy or safety expectations, development timelines, regulatory approvals, commercialization prospects, or partnership opportunities could be adversely affected.

Risk Level: Medium

Company Commentary

• Suven will present five scientific posters covering its neuroscience pipeline during AAIC 2026.
• The company aims to share ongoing Phase-3 Masupirdine progress and Phase-2 Usmarapride development updates.
• Management will interact with global researchers, clinicians and industry participants.
• The conference will also serve as a platform to explore strategic partnering and collaboration opportunities for its CNS portfolio.